Want to see ASH full AI Analyst Report?
EBITDA by Segment
Presents each business segment’s operating profitability before interest, taxes, depreciation, and amortization, highlighting which divisions generate the most cash and which face margin pressure. Clarifies where Ashland has pricing power or efficiency advantages and where cost control or reinvestment may be required.Mid‑2025 contains massive, clearly one‑off EBITDA hits in Life Sciences and Specialty Additives that materially distort trending profitability; strip those charges out and consumer‑facing businesses—Life Sciences and Personal Care—display resilient margins and innovation‑led sales momentum. Management pins the short‑term drag on execution (Hopewell ramp, Calvert City outage) and a discrete bad‑debt reserve, trimmed guidance but kept long‑term manufacturing savings and cash‑conversion targets intact. The stock is thus more an execution call than demand: performance will hinge on timely operational fixes and margin recovery.
Date | Life Sciences | Personal Care | Speciality Additives | Intermediates | Unallocated & Other |
|---|---|---|---|---|---|
Mar 31, 2026 | $49.00M | $42.00M | $8.00M | $5.00M | -$20.00M |
Dec 31, 2025 | $31.00M | $26.00M | $10.00M | $1.00M | -$26.00M |
Sep 30, 2025 | $52.00M | $43.00M | $21.00M | $6.00M | -$11.00M |
Jun 30, 2025 | -$321.00M | $40.00M | -$309.00M | $7.00M | -$49.00M |
Mar 31, 2025 | $54.00M | $43.00M | $23.00M | $2.00M | -$11.00M |
Dec 31, 2024 | $28.00M | $29.00M | $11.00M | $6.00M | -$202.00M |
Sep 30, 2024 | $57.00M | $34.00M | $24.00M | $11.00M | -$41.00M |
Jun 30, 2024 | $58.00M | $51.00M | $33.00M | $9.00M | -$151.00M |
Mar 31, 2024 | $66.00M | $45.00M | $26.00M | $12.00M | -$45.00M |
Dec 31, 2023 | $48.00M | $22.00M | $6.00M | $10.00M | -$27.00M |